---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-013339"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:16:19.433666+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences closes private placement of 10M shares to Executive Chairman at $6.51

## Summary
- Robert W. Duggan, Executive Chairman and majority stockholder, purchased 10,022,937 shares at $6.51 per share.
- Price represents a ~1% premium over the $6.44 NASDAQ closing price on April 28, 2023.
- Transaction under Securities Purchase Agreement dated April 30, 2023, consummated on May 9, 2023.

## SEC filing metadata
- accession: 0001437749-23-013339
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774923013339/0001437749-23-013339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774923013339/plse20230509_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-013339
- JSON: https://secwatch.observer/filing/0001437749-23-013339.json
- Plain text: https://secwatch.observer/filing/0001437749-23-013339.txt

## Key facts
- Material Agreements
  PULSE BIOSCIENCES, INC. entered into Securities Purchase Agreement with Robert W. Duggan (effective 2023-04-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Robert W. Duggan
  - Effective: 2023-04-30
  source text: On May 9, 2023, the transactions contemplated by that certain Securities Purchase Agreement dated as of April 30, 2023 (the “Purchase Agreement”) between Pulse Biosciences, Inc. (the “Company”) and Robert W. Duggan, the Company’s Executive Chairman of the Board of Directors and majority stockholder of the Company, were consummated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774923013339/0001437749-23-013339-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.